Search Results 331-340 of 17562 for what is vedolizumab

  1. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

    A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment.

  2. A Study of the Long-Term Safety and Effectiveness of Adalimumab for Repeat Treatment of Pediatric Patients with Ulcerative Colitis - Mayo Clinic

    A Study of the Long-Term Safety and Effectiveness of Adalimumab for Repeat Treatment of Pediatric Patients with Ulcerative Colitis · Overview · Participation ...

  3. A Study to Evaluate the Safety and Effectiveness of Ustekinumab Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    ... vedolizumab at a dose approved for the treatment of UC, and has a documented history of failure to respond to or tolerate such treatment; OR has not had ...

  4. Rectal bleeding Causes - Mayo Clinic

    Ulcerative colitis — a disease that causes ulcers and swelling called inflammation in the lining of the large intestine. Causes shown here are commonly ...

  5. Discovery's Edge: Hope For Healing With Regenerative Medicine - Mayo Clinic News Network

    Crohn's-related wounds may have met their match in a pioneering regenerative therapy thanks to truly collaborative team science.

  6. Natalizumab (intravenous route) - Side effects & uses - Mayo Clinic

    Vedolizumab. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions ...

  7. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission - Mayo Clinic

    ... Crohn's disease or ulcerative colitis [UC]) in symptomatic remission ... Vedolizumab 300 mg q4wk >15mg/mlUstekinumab 90 mg q4wk/IV re induction >1.2 ...

  8. Jana G. Al Hashash, M.D., M.S. - Doctors and Medical Staff - Mayo Clinic

    ... Crohn's disease and ulcerative colitis. Prior to joining the Inflammatory Bowel Disease Center at Mayo Clinic, she was an Assistant Professor of Medicine at ...

  9. AMG 181 in Subjects with Moderate to Severe Crohn's Disease - Mayo Clinic

    After completing all screening assessments and meeting all eligibility criteria, subjects will be randomized to receive placebo or AMG 181 at various doses per ...

  10. A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Clinical Trials · A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease · More about ...